FDA Accepts Supplemental Application for XATMEP (Methotrexate Sodium)
The FDA has accepted a supplemental application for XATMEP, a formulation of methotrexate sodium.
Published: July 21, 2026
Updated: July 21, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Chemotherapy
Asset: AZURITY
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
AZURITY
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental application for XATMEP is significant as it may expand treatment options in oncology, particularly for pediatric patients. This could strengthen AZURITY's competitive position in a critical therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for the FDA's final decision on the supplemental application and any subsequent market entry timelines.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.